[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Service de neurologie, fédération de neuro-oncologie, hôpital Pasteur, 30, voie Romaine, 06002 Nice, France. Electronic address: lebrun-frenay.c@chu-nice.fr.
C
C
Lebrun-Frenay
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005910:Glioma / Q000628:therapy*; D006801:Humans; D000077204:Temozolomide
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide